Therefore, Mdm2 haploinsufficiency significantly alters tumor spectrum toward lymphoma and away from sarcoma in specific Arf/p53 genotypes, but only modestly influences or has no effect on tumor spectrum in other Arf/p53 genotypes. This evidence concerns the gene CDKN2A and sarcoma.